Different effects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: studies with extracellular matrix covered with endothelial cells
- PMID: 3551181
Different effects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: studies with extracellular matrix covered with endothelial cells
Abstract
Cultured endothelial cells produce an extracellular matrix (ECM) which activates platelets, similarly to deendothelialized vascular segments. Platelet-rich plasma (PRP) was incubated with endothelial cells cultures seeded in various densities on ECM. The interaction of the platelets with this artificial intima was evaluated by phase microscopy and by thromboxane A2 (TXA2) and prostacyclin (PGI2) measurement. Large platelet aggregates were formed on exposed ECM. Platelets aggregation but not adhesion on the ECM was markedly inhibited by the presence of endothelial cells. Pretreatment of the endothelial cells with 0.1 mM aspirin reduced their PGI2 synthesis and was associated with platelet aggregation on the ECM. 10 microM dipyridamole markedly inhibited platelet activation by ECM when the drug was added to citrated whole blood before PRP preparation. UD-CG 115 which elevates cyclic AMP in cardiac muscle, inhibited platelet aggregation and TXA2 production induced by ECM, in the presence as well as in the absence of endothelial cells, without any effect on endothelial PGI2 production.
Similar articles
-
The inhibitory effect of aspirin on human endothelial cells.Thromb Haemost. 1978 Aug 31;40(1):103-10. Thromb Haemost. 1978. PMID: 364762
-
A new in vitro model for investigation of tumor cell-platelet-endothelial cell interactions and concomitant eicosanoid biosynthesis.Cancer Res. 1987 May 1;47(9):2425-32. Cancer Res. 1987. PMID: 3552214
-
In vitro studies of thromboresistance: the role of prostacyclin (PGI2) in platelet adhesion to cultured normal and virally transformed human vascular endothelial cells.Lab Invest. 1980 Mar;42(3):366-74. Lab Invest. 1980. PMID: 6244462
-
Role of heparanase in platelet and tumor cell interactions with the subendothelial extracellular matrix.Semin Thromb Hemost. 1987 Oct;13(4):475-88. doi: 10.1055/s-2007-1003524. Semin Thromb Hemost. 1987. PMID: 3321438 Review.
-
Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.Circulation. 1980 Dec;62(6 Pt 2):V19-25. Circulation. 1980. PMID: 7002350 Review.
Cited by
-
Targeting phosphodiesterases in anti-platelet therapy.Handb Exp Pharmacol. 2012;(210):225-38. doi: 10.1007/978-3-642-29423-5_9. Handb Exp Pharmacol. 2012. PMID: 22918733 Free PMC article. Review.
-
Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo.Br J Clin Pharmacol. 1990 Aug;30(2):179-86. doi: 10.1111/j.1365-2125.1990.tb03763.x. Br J Clin Pharmacol. 1990. PMID: 2206782 Free PMC article. Clinical Trial.
-
Envelope glycoprotein of avian hemangioma retrovirus induces a thrombogenic surface on human and bovine endothelial cells.J Virol. 1990 Aug;64(8):4029-32. doi: 10.1128/JVI.64.8.4029-4032.1990. J Virol. 1990. PMID: 2164612 Free PMC article.
-
No impact of polymorphism in the phosphodiesterase 5A gene in Cavalier King Charles Spaniels on pimobendan-induced inhibition of platelet aggregation response.J Vet Intern Med. 2023 Nov-Dec;37(6):2145-2156. doi: 10.1111/jvim.16871. Epub 2023 Sep 24. J Vet Intern Med. 2023. PMID: 37743723 Free PMC article.
-
Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.Drugs Aging. 1994 May;4(5):417-41. doi: 10.2165/00002512-199404050-00007. Drugs Aging. 1994. PMID: 8043944 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials